IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label Big Pharma. Show all posts
Showing posts with label Big Pharma. Show all posts
Wednesday, 30 May 2018

FDA Attempts to Shame Pharmacuetical and Biotechnology Companies

›
The U.S. Federal Drug Administration (FDA) recently decided to try to “shame” some pharmaceutical and biotechnology companies for failin...
Wednesday, 2 February 2011

Farewell Sandwich

›
In the midst of discussions about the future of IP tax and incentives in the UK comes the news that Pfizer is closing its UK R&D facilit...
Monday, 31 August 2009

Branded Generics; did The Economist Get It Right?

›
Once again the quality press seems uncertain about intellectual property, and in particular the role of trade marks in the drug business. Th...
1 comment:
Monday, 23 March 2009

Two Final Thoughts on Big Pharma Acquisitions

›
A coda in two parts to my recent postings on the mega-transactions by Pfizer, Merck and Roche of Wyeth, Schering-Plough, and Genentech, resp...
›
Home
View web version
Powered by Blogger.